NMN Supplements: What 18 Human Studies Actually Show

NMN (nicotinamide mononucleotide) supplements have attracted intense interest as a potential way to support energy metabolism and slow aspects of biological aging. With over a dozen human clinical trials now completed, there is enough evidence to move beyond anecdote and examine what the research actually shows.

This article reviews all 18 human studies of NMN, focusing on four key findings: what NMN does to NAD+ levels in blood versus muscle, what the placebo-controlled trials show for physical performance and metabolic health, the long-term safety questions raised by the niacin literature, and the practical bottom line for supplementation.

What Are NMN Supplements and Why Are People Excited?

NMN supplements are specifically formulated doses of the molecule nicotinamide mononucleotide. The body naturally produces this molecule, but it can also be taken as a supplement. Widespread excitement about NMN began around 2019 when Harvard professor David Sinclair discussed the molecule on a popular podcast. While that context is not an authoritative scientific source, Sinclair's comments drove substantial public interest — and, importantly, catalysed a meaningful slate of human clinical research that can now be examined directly.

NMN functions as a precursor molecule the body uses to power energy production and metabolic processes. Think of NMN as the crude oil and NAD (nicotinamide adenine dinucleotide) as the refined fuel — the body can only produce NAD if NMN is present. NAD itself is involved in energy metabolism, DNA repair, cellular stress responses, and gene expression. As people age, endogenous NMN production declines. The theoretical basis for supplementation is that raising NMN intake could help sustain NAD levels and, in turn, support the processes that depend on them.

At the time Sinclair was generating public interest, virtually no human research had been performed. A single mouse study had found that NMN supplements reduced age-related decline in muscle performance — it did not extend life, but it did appear to reduce the detrimental impact of aging on metabolism and muscle function in rodents. It is those early mouse results, amplified by media coverage, that created the current market for NMN supplements. The question is whether human trials have borne that promise out.

The Results of 18 Human NMN Studies

After the initial rodent literature, researchers have now conducted 18 human studies of NMN. The hoped-for benefits span four domains: muscle performance, resilience to illness and infection, energy levels, and metabolic health. What do placebo-controlled trials actually show?

The confounding variable of the placebo effect

Before examining the studies, it is worth understanding why placebo control is essential — and why the large volume of positive anecdotal reports online should be treated cautiously.

Search for NMN and you will find health influencers, personal blogs, and supplement review pages full of testimonials reporting higher energy, improved recovery, and a variety of beneficial effects. The problem is the placebo effect. The placebo effect is a well-established phenomenon in which patients who believe they are taking an active treatment experience real, measurable improvements — even when the treatment has no biological activity.

A well-known trial illustrates the scale of this effect. A study on knee osteoarthritis pain examined the combination of glucosamine and chondroitin and found that 60% of patients taking the active treatment reported a significant reduction in pain. But 60% of patients taking a dummy placebo — a pill with zero biological effect — also reported the same reduction in pain. Simply believing they were taking something beneficial was enough to produce a measurable improvement in how those patients felt.

The placebo effect is one of the greatest unsolved mysteries in medical science, and it operates as a confounding factor in every medicinal and supplement trial. This is precisely why "placebo-controlled" is such an important criterion for a well-designed study. Without comparing the supplement to a placebo under blinded conditions, it is impossible to know whether the results reflect genuine biological activity or expectation bias.

Examining the eighteen human NMN studies

With that context established, several factors need to be considered when evaluating each trial.

The first is safety. All eighteen human studies of NMN were short-term studies, and none of them reported significant harmful side effects within the doses tested. This is an encouraging sign: NMN does not appear to cause acute harm at the doses and timeframes studied. However, short-term tolerability is not the same as long-term safety — a distinction that becomes important later in this review.

The trial design matters enormously. The gold standard for clinical evidence is the Randomised Controlled Trial (RCT), in which participants are randomly allocated to either the active treatment or the placebo. Neither the participants nor the researchers know who received which — this double-blind design prevents conscious or unconscious bias from influencing the results.

Of the eighteen human trials, four were not randomised and controlled. These four have been excluded from the analysis below, as they cannot be considered reliable evidence of a treatment effect. The remaining fourteen RCTs form the basis of the evaluation.

A critical question before any downstream effect can be evaluated is whether taking NMN actually raises NAD levels. NAD is the molecule with the biological activity; NMN is merely the building block. If oral NMN supplementation did not increase NAD, the entire premise would collapse — the supplement would simply not enter the body in the way required to have any effect.

On this question, the news is consistently positive. Every one of the fourteen RCTs that measured blood NAD levels found an increase after NMN supplementation. However, blood NAD is not necessarily the outcome of greatest interest. If the goal is to improve muscle performance, what matters is muscle NAD — and only one of the fourteen studies took muscle biopsies to directly measure it. That single study did not show an increase in muscle NAD following NMN supplementation.

This is a meaningful gap in the evidence. A 2022 report added relevant context: older adults who exercise regularly had muscle NAD levels comparable to those of younger adults. That finding raises an important question — if the same outcome can be achieved through a consistent exercise routine, what additional role does NMN supplementation play?

The controversial muscle factor

A separate hypothesis is that NMN might improve physical performance through a mechanism other than simply raising NAD in muscle tissue. Several of the fourteen RCTs examined this question directly, looking at 16 different measures of physical performance in total.

Of those 16 performance measures, only four showed any change compared to placebo — and one of those four was highly controversial. The twelve measures that showed no effect have been set aside; the focus here is on those remaining four.

The most disputed result came from the tenth human trial, conducted in India. The measure in question was walking distance over a set period — the study suggested NMN improved walking stamina and speed. However, significant methodological concerns were raised. The participants had baseline walking speeds so slow that, despite being middle-aged, they performed more like people in their eighties. Combined with other data irregularities in the trial, the results were subsequently discredited by researchers and excluded from the consensus picture.

Examining metabolic health

Mouse studies had suggested NMN might also support metabolic health, so many of the human RCTs tracked metabolic markers including LDL cholesterol, fasting glucose, insulin levels, and HbA1c.

The pattern mirrored what was found for physical performance: most outcomes showed no meaningful change. Of 28 metabolic factors monitored across the trials, 23 showed zero change attributable to NMN. One factor — insulin sensitivity in one study — was actually negatively affected. Only four markers showed a benefit, and one of those requires careful interpretation.

The anomalous finding came from a control (placebo) group that showed a statistically significant worsening of insulin sensitivity. Viewed in comparison, this made the NMN group look as though it had improved. In reality, NMN had no effect on insulin sensitivity — something unusual happened in the control group, and the apparent difference was an artefact of that, not a genuine treatment benefit.

A handful of additional outcomes were examined across the studies:

• Overall fatigue and energy levels: Both NMN groups and control groups reported similar rates of improvement, consistent with a placebo effect rather than a genuine pharmacological benefit.
• Arterial stiffness: Two studies examined this outcome. One found no change; the other found a statistically insignificant improvement that did not meet the threshold for a meaningful result.
• Hearing and cognition: No changes were observed in either domain.

Taken together, the metabolic evidence does not support a meaningful benefit from NMN supplementation on the outcomes that were tested.

Revisiting Safety

All eighteen studies found NMN to be well-tolerated in the short term. But since anyone considering NMN supplementation would likely be taking it over months or years, the long-term picture matters considerably more.

One area of concern comes from the niacin literature. NMN and niacin are both forms of Vitamin B3. Studies of high-dose vitamin B3 supplementation found that it increased all-cause mortality by 10%. Critically, these findings involved megadoses of 1–3 grams of niacin per day — a range far above what most people would consider a supplement dose. At a modest, evidence-aligned dose, this risk profile is not a concern.

However, most commercially available NMN supplements recommend a daily dose of 1,000 mg (1 gram) — a level that represents 6,250% of the recommended daily intake for niacin. This places typical NMN supplement doses squarely within the range studied in the high-dose niacin trials.

A 2024 study reinforced this concern. Researchers examined the metabolic byproducts of vitamin B3 consumption and found that two metabolites — 2PY and 4PY — increased with vitamin B3 intake. These metabolites appear to worsen blood vessel inflammation and may increase the risk of cardiovascular death. The study raises a plausible mechanism by which chronically high-dose B3 supplementation (including high-dose NMN) could pose long-term cardiovascular risk.

Four Key Takeaways

Reviewing all eighteen human studies, four conclusions emerge:

#1: NMN appears to be safe in the short term. No serious adverse effects were reported across the studies at the doses tested. Short-term supplementation at studied doses does not appear to cause harm.

#2: There may be very limited evidence of muscle function improvement, but the overall picture is weak. Of 16 physical performance measures examined, only a handful showed any change from placebo — and the most dramatic finding (walking performance in the India trial) has been discredited. One study specifically measuring muscle NAD after NMN supplementation found no increase, which undermines the primary proposed mechanism for muscle benefit.

#3: NMN is unlikely to deliver meaningful metabolic benefits. Of 28 metabolic factors monitored across the trials, 23 showed no change. One appeared to worsen insulin sensitivity. The four positive findings require careful contextual interpretation and do not constitute reliable evidence of a treatment effect.

#4: Long-term safety remains an open question, particularly at the high doses recommended by most supplement companies. The niacin literature and the 2024 metabolite study both point to potential cardiovascular concerns with chronic, high-dose vitamin B3 supplementation — the same dosage range marketed for NMN. No long-term human RCTs of NMN currently exist to resolve this uncertainty.

Based on the current evidence, the existing body of human trials does not support supplementing with NMN — particularly at the 1,000 mg doses widely recommended by supplement manufacturers. The best-supported approach to maintaining NAD levels as people age remains consistent exercise and a nutrient-rich diet, both of which have substantially more evidence behind them than NMN supplementation. Anyone considering NMN should discuss it with their doctor, particularly given the unresolved long-term safety questions.

Sources

1. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men: https://pubmed.ncbi.nlm.nih.gov/31685720/
2. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women: https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/
3. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8265078/
4. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study: https://pmc.ncbi.nlm.nih.gov/articles/PMC8877443/
5. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects: https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.868640/full
6. A Multicentre, Randomised, Double-Blind, Parallel Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle-Aged and Older Adults: https://pmc.ncbi.nlm.nih.gov/articles/PMC9261366/
7. Clinical evaluation of changes in biomarkers by oral intake of NMN: https://www.toukastress.jp/webj/article/2022/GS22-16.pdf
8. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women: https://pmc.ncbi.nlm.nih.gov/articles/PMC9400576/
9. Nicotinamide Mononucleotide Is Safely Metabolized and Significantly Reduces Blood Triglyceride Levels in Healthy Individuals: https://pmc.ncbi.nlm.nih.gov/articles/PMC9534732/
10. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial: https://pmc.ncbi.nlm.nih.gov/articles/PMC9735188/
11. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men: https://pmc.ncbi.nlm.nih.gov/articles/PMC9158788/
12. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults: https://pubmed.ncbi.nlm.nih.gov/35182418/
13. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study: https://pubmed.ncbi.nlm.nih.gov/36443648/
14. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial: https://pmc.ncbi.nlm.nih.gov/articles/PMC9935856/
15. Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study: https://pubmed.ncbi.nlm.nih.gov/36740954/
16. Nicotinamide mononucleotide (NMN) intake increases plasma NMN and insulin levels in healthy subjects: https://pubmed.ncbi.nlm.nih.gov/37344088/
17. Fingerstick blood assay maps real-world NAD+ disparity across gender and age: https://onlinelibrary.wiley.com/doi/10.1111/acel.13965
18. NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension: https://www.nature.com/articles/s41392-023-01577-3
19. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice: https://pmc.ncbi.nlm.nih.gov/articles/PMC5668137/
20. 17-a-estradiol late in life extends lifespan in aging UM-HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex: https://onlinelibrary.wiley.com/doi/10.1111/acel.13328
21. LONG-TERM NMN TREATMENT INCREASES LIFESPAN AND HEALTHSPAN IN MICE IN A SEX DEPENDENT MANNER: https://academic.oup.com/innovateage/article/7/Supplement_1/1077/7490297?login=false
22. β-Nicotinamide mononucleotide supplementation prolongs the lifespan of prematurely aged mice and protects colon function in aging mice: https://pubs.rsc.org/en/content/articlehtml/2024/fo/d3fo05221d
23. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis: https://pubmed.ncbi.nlm.nih.gov/16495392/
24. Nicotinamide riboside does not alter mitochondrial respiration, content, or morphology in skeletal muscle from obese and insulin-resistant men: https://pubmed.ncbi.nlm.nih.gov/31710095/
25. Healthy aging and muscle function are positively associated with NAD+ abundance in humans: https://www.nature.com/articles/s43587-022-00174-3
26. Supplemental Vitamins and Minerals for CVD Prevention and Treatment: https://www.sciencedirect.com/science/article/pii/S0735109718345601?via%3Dihub
27. Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations: https://pmc.ncbi.nlm.nih.gov/articles/PMC9345839/
28. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk: https://pubmed.ncbi.nlm.nih.gov/38374343/